Mucosal vaccines: Novel strategies and applications for the control of pathogens and tumors at mucosal sites

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2175-2187

  Nizard, Mevyn ^a   Diniz, Mariana O ^a,b   Roussel, Helene ^a,c   Tran, Thi ^a   Ferreira, Luis C S ^b   Badoual, Cecile ^a,c   Tartour, Eric ^a,c  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cancer vaccines; Homing molecules; Immunization routes; Mucosal adjuvants; Mucosal imprinting; Mucosal vaccines; Resident memory T cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALUMINUM POTASSIUM SULFATE; AS 04; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CHOLERA VACCINE; COLISTIN; CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; GLUCOPYRANOSYL LIPID ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; ISCOM; LIPOSOME; MELANOMA ANTIGEN 3; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; POLYMYXIN B; PROTEIN E6; PROTEIN E7; ROTAVIRUS VACCINE; TECEMOTIDE; TOLL LIKE RECEPTOR AGONIST; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIROSOME; WART VIRUS VACCINE; VACCINE;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLORECTAL CANCER; CROSS PRESENTATION; DENDRITIC CELL; ENCAPSULATION; HEAD AND NECK CANCER; HERPES VIRUS INFECTION; HUMAN; IMMUNIZATION; INTESTINE FLORA; LUNG CANCER; LYMPHOCYTE MIGRATION; LYMPHOID TISSUE; MEMORY T LYMPHOCYTE; MUCOSA ASSOCIATED LYMPHOID TISSUE; MUCOSAL ADMINISTRATION; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; MUCOSAL DRUG ADMINISTRATION;

ADMINISTRATION, MUCOSAL; ANIMALS; HUMANS; IMMUNITY, MUCOSAL; VACCINES;

EID: 84908374940     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29269     Document Type: Review

References (180)

1. Sato S, Kiyono H. The mucosal immune system of the respiratory tract. Current opinion in virology 2012; 2:225-32.
2. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009; 70:505-15; PMID:19906191; http://dx.doi.org/10.1111/j.1365-3083.2009.02319.x
3. Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009; 21:352-8; PMID:19493665; http://dx.doi.org/10.1016/j.coi.2009.04.002
4. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178-87; PMID:22150036; http://dx.doi.org/10.1056/NEJMoa1101245
5. http://www.clinicaltrials.gov/ct.
6. Nardelli-Haefliger D, Dudda JC, Romero P. Vaccination route matters for mucosal tumors. Science translational medicine 2013; 5:172fs4.
7. Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 2010; 32:946-58; PMID:20191626
8. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004; 4:699-710; PMID:15343369; http://dx.doi.org/10.1038/nri1439
9. Nizard M, Sandoval F, Badoual C, Pere H, Terme M, Hans S, Benhamouda N, Granier C, Brasnu D, Tartour E. Immunotherapy of HPV-associated head and neck cancer: Critical parameters. Oncoimmunology 2013; 2:e24534; PMID:23894716; http://dx.doi.org/10.4161/onci.24534
10. Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol 2006; 34:599-608; PMID:17067945; http://dx.doi.org/10.1080/01926230600865531
11. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 2000; 68:1-8; PMID:10859525; http://dx.doi.org/10.1159/000028109
12. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2008; 26:4410-7.
13. Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine 2012; 30:142-54; PMID:22085556; http://dx.doi.org/10.1016/j.vaccine.2011.11.003
14. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005; 174:4453-60; PMID:15814663; http://dx.doi.org/10.4049/jimmunol.174.8.4453
15. Fritz JH, Le Bourhis L, Magalhaes JG, Philpott DJ. Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat. Trends Immunol 2008; 29:41-9; PMID:18054284; http://dx.doi.org/10.1016/j.it.2007.10.002
16. Kraehenbuhl JP, Neutra MR. Epithelial M cells: differentiation and function. Annu Rev Cell Dev Biol 2000; 16:301-32; PMID:11031239; http://dx.doi.org/10.1146/annurev.cellbio.16.1.301
17. Siebers A, Finlay BB. M cells and the pathogenesis of mucosal and systemic infections. Trends Microbiol 1996; 4:22-9; PMID:8824791; http://dx.doi.org/10.1016/0966-842X(96)81501-0
18. Contractor N, Louten J, Kim L, Biron CA, Kelsall BL. Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGFbeta, and prostaglandin E2 in conditioning a unique mucosal pDC phenotype. J Immunol 2007; 179:2690-4; PMID:17709480; http://dx.doi.org/10.4049/jimmunol.179.5.2690
19. Salazar-Gonzalez RM, Niess JH, Zammit DJ, Ravindran R, Srinivasan A, Maxwell JR, Stoklasek T, Yadav R, Williams IR, Gu X, et al. CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches. Immunity 2006; 24:623-32; PMID:16713979; http://dx.doi.org/10.1016/j.immuni.2006.02.015
20. Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyer's patch dendritic cells. J Immunol 2001; 166:4884-90; PMID:11290765; http://dx.doi.org/10.4049/jimmunol.166.8.4884
21. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Márquez G, Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198:963-9; PMID:12963696; http://dx.doi.org/10.1084/jem.20031244
22. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, Berg PL, Davidsson T, Powrie F, Johansson-Lindbom B, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 2008; 205:2139-49; PMID:18710932; http://dx.doi.org/10.1084/jem.20080414
23. Svensson M, Johansson-Lindbom B, Zapata F, Jaensson E, Austenaa LM, Blomhoff R, Agace WW. Retinoic acid receptor signaling levels and antigen dose regulate gut homing receptor expression on CD8+ T cells. Mucosal Immunol 2008; 1:38-48; PMID:19079159; http://dx.doi.org/10.1038/mi.2007.4
24. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity 2013; 39:1095-107; PMID:24290911; http://dx.doi.org/10.1016/j.immuni.2013.11.003
25. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol 2008; 8:421-34; PMID:18483500; http://dx.doi.org/10.1038/nri2322
26. Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol 2010; 8:656-67; PMID:20694027; http://dx.doi.org/10.1038/nrmicro2384
27. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011; 239:125-48; PMID:21198669; http://dx.doi.org/10.1111/j.1600-065X.2010.00970.x
28. Hammerschmidt SI, Ahrendt M, Bode U, Wahl B, Kremmer E, Förster R, Pabst O. Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 2008; 205:2483-90; PMID:18852290; http://dx.doi.org/10.1084/jem.20080039
29. Mueller SN, Germain RN. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 2009; 9:618-29; PMID:19644499
30. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314:1157-60; PMID:17110582; http://dx.doi.org/10.1126/science.1132742
31. Gohda M, Kunisawa J, Miura F, Kagiyama Y, Kurashima Y, Higuchi M, Ishikawa I, Ogahara I, Kiyono H. Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses. J Immunol 2008; 180:5335-43; PMID:18390715; http://dx.doi.org/10.4049/jimmunol.180.8.5335
32. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 2005; 206:83-99; PMID:16048543; http://dx.doi.org/10.1111/j.0105-2896.2005.00278.x
33. McGuckin MA, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011; 9:265-78; PMID:21407243; http://dx.doi.org/10.1038/nrmicro2538
34. Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol 2008; 29:505-13; PMID:18835748; http://dx.doi.org/10.1016/j.it.2008.07.008
35. Meeusen EN. Exploiting mucosal surfaces for the development of mucosal vaccines. Vaccine 2011; 29:8506-11; PMID:21945494; http://dx.doi.org/10.1016/j.vaccine.2011.09.010
36. Mantis NJ, Rol N, Corthésy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011; 4:603-11; PMID:21975936; http://dx.doi.org/10.1038/mi.2011.41
37. Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH. Structure and function of bronchus-associated lymphoid tissue (BALT). Crit Rev Immunol 1989; 9:119-50; PMID:2663024
38. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9:981-7; PMID:18711435; http://dx.doi.org/10.1038/ni.f.208
39. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, Ward RL, Woodland DL, Lefranc¸ois L. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 2004; 172:4875-82; PMID:15067066; http://dx.doi.org/10.4049/jimmunol.172.8.4875
40. Ariotti S, Haanen JB, Schumacher TN. Behavior and function of tissue-resident memory T cells. Adv Immunol 2012; 114:203-16; PMID:22449783; http://dx.doi.org/10.1016/B978-0-12-396548-6.00008-1
41. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009; 10:524-30; PMID:19305395; http://dx.doi.org/10.1038/ni.1718
42. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003; 18:593-603; PMID:12753737; http://dx.doi.org/10.1016/S1074-7613(03)00112-2
43. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008; 319:198-202; PMID:18187654; http://dx.doi.org/10.1126/science.1151869
44. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefranc¸ois L, Farber DL. Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011; 187:5510-4; PMID:22058417; http://dx.doi.org/10.4049/jimmunol.1102243
45. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS. Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 2011; 6:e16245; PMID:21298112; http://dx.doi.org/10.1371/journal.pone.0016245
46. Hofmann M, Pircher H. E-cadherin promotes accumulation of a unique memory CD8 T-cell population in murine salivary glands. Proc Natl Acad Sci U S A 2011; 108:16741-6; PMID:21930933; http://dx.doi.org/10.1073/pnas.1107200108
47. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, Wang J, Casey KA, Barber DL, Kawamura KS, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med 2010; 207:553-64; PMID:20156972; http://dx.doi.org/10.1084/jem.20090858
48. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol 2013; 13:309-20; PMID:23598650; http://dx.doi.org/10.1038/nri3442
49. Carbone FR, Mackay LK, Heath WR, Gebhardt T. Distinct resident and recirculating memory T cell subsets in non-lymphoid tissues. Curr Opin Immunol 2013; 25:329-33; PMID:23746791; http://dx.doi.org/10.1016/j.coi.2013.05.007
50. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009; 9:153-61; PMID:19240755; http://dx.doi.org/10.1038/nri2496
51. Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107:3258-64; PMID:16373659; http://dx.doi.org/10.1182/blood-2005-11-4374
52. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21:527-38; PMID:15485630; http://dx.doi.org/10.1016/j.immuni.2004.08.011
53. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007; 8:285-93; PMID:17259988; http://dx.doi.org/10.1038/ni1433
54. Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 2002; 32:1445-54; PMID:11981833; http://dx.doi.org/10.1002/1521-4141(200205)32:5〈1445::AIDIMMU1445〉3.0.CO;2-E
55. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192:761-8; PMID:10974041; http://dx.doi.org/10.1084/jem.192.5.761
56. Campbell DJ, Butcher EC. Rapid acquisition of tis-sue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002; 195:135-41; PMID:11781372; http://dx.doi.org/10.1084/jem.20011502
57. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004; 172:857-63; PMID:14707056; http://dx.doi.org/10.4049/jimmunol.172.2.857
58. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12:592-605; PMID:22828912; http://dx.doi.org/10.1038/nri3251
59. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996; 184:1879-90; PMID:8920875; http://dx.doi.org/10.1084/jem.184.5.1879
60. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci U S A 1998; 95:1709-14; PMID:9465081; http://dx.doi.org/10.1073/pnas.95.4.1709
61. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008; 1:11-22; PMID:19079156; http://dx.doi.org/10.1038/mi.2007.6
62. Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 2003; 111:1001-10; PMID:12671049; http://dx.doi.org/10.1172/JCI17244
63. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 2000; 165:2943-9; PMID:10975800; http://dx.doi.org/10.4049/jimmunol.165.6.2943
64. Cha HR, Ko HJ, Kim ED, Chang SY, Seo SU, Cuburu N, Ryu S, Kim S, Kweon MN. Mucosa-associated epithelial chemokine/CCL28 expression in the uterus attracts CCR10+ IgA plasma cells following mucosal vaccination via estrogen control. J Immunol 2011; 187:3044-52; PMID:21832166; http://dx.doi.org/10.4049/jimmunol.1100402
65. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, Vimeux L, Marañon C, Czerkinsky C, Hosmalin A, Anjuère F. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010; 28:5582-90; PMID:20600505; http://dx.doi.org/10.1016/j.vaccine.2010.06.033
66. Ruane D, Brane L, Reis BS, Cheong C, Poles J, Do Y, Zhu H, Velinzon K, Choi JH, Studt N, et al. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med 2013; 210:1871-88; PMID:23960190; http://dx.doi.org/10.1084/jem.20122762
67. Hervouet C, Luci C, Bekri S, Juhel T, Bihl F, Braud VM, Czerkinsky C, Anjuère F. Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells. Mucosal Immunol 2014; 7:280-91; PMID:23801305; http://dx.doi.org/10.1038/mi.2013.45
68. Marks E, Helgeby A, Andersson JO, Schön K, Lycke NY. CD4+ T-cell immunity in the female genital tract is critically dependent on local mucosal immunization. Eur J Immunol 2011; 41:2642-53; PMID:21681740; http://dx.doi.org/10.1002/eji.201041297
69. Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun 1998; 66:3390-6; PMID:9632610
70. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 2012; 149:1578-93; PMID:22726443; http://dx.doi.org/10.1016/j.cell.2012.04.037
71. Kamada N, Núñez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014; 146:1477-88; PMID:24503128; http://dx.doi.org/10.1053/j.gastro.2014.01.060
72. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98; PMID:20107214; http://dx.doi.org/10.1056/NEJMoa0904797
73. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M, Von Andrian UH. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424:88-93; PMID:12840763; http://dx.doi.org/10.1038/nature01726
74. Luiz WB, Cavalcante RC, Paccez JD, Souza RD, Sbrogio-Almeida ME, Ferreira RC, Ferreira LC. Boosting systemic and secreted antibody responses in mice orally immunized with recombinant Bacillus subtilis strains following parenteral priming with a DNA vaccine encoding the enterotoxigenic Escherichia coli (ETEC) CFA/I fimbriae B subunit. Vaccine 2008; 26:3998-4005; PMID:18597902; http://dx.doi.org/10.1016/j.vaccine.2008.05.030
75. Im EJ, Borducchi EN, Provine NM, McNally AG, Li S, Frankel FR, Barouch DH. An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virus-specific mucosal immunity than DNA vaccines in mice. J Virol 2013; 87:4751-5; PMID:23388715; http://dx.doi.org/10.1128/JVI.03085-12
76. Neeson P, Boyer J, Kumar S, Lewis MG, Mattias L, Veazey R, Weiner D, Paterson Y. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype. Virology 2006; 354:299-315; PMID:16904153; http://dx.doi.org/10.1016/j.virol.2006.06.036
77. Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 2013; 97:1231-9; PMID:23212671; http://dx.doi.org/10.1007/s00253-012-4575-1
78. Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65:3328-36; PMID:9234794
79. Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol 2013; 191:2486-94; PMID:23885108; http://dx.doi.org/10.4049/jimmunol.1300954
80. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010; 5:e13162; PMID:20976273; http://dx.doi.org/10.1371/journal.pone.0013162
81. Baron SD, Singh R, Metzger DW. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 2007; 75:2152-62; PMID:17296747; http://dx.doi.org/10.1128/IAI.01606-06
82. Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Crossprotection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 2010; 28:7690-8; PMID:20870054; http://dx.doi.org/10.1016/j.vaccine.2010.09.019
83. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal immunization promotes th17 immune responses. J Immunol 2009; 183:6933-8; PMID:19890060; http://dx.doi.org/10.4049/jimmunol.0901144
84. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34:149-62; PMID:21349428; http://dx.doi.org/10.1016/j.immuni.2011.02.012
85. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, et al.; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-9; PMID:17006279; http://dx.doi.org/10.1097/01.inf.0000237829.66310.85
86. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 2008; 105:1644-9; PMID:18227512; http://dx.doi.org/10.1073/pnas.0708684105
87. Kim SH, Kim JY, Choi Y, Nguyen HH, Song MK, Chang J. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One 2013; 8:e75460; PMID:24086536; http://dx.doi.org/10.1371/journal.pone.0075460
88. Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest 2012; 122:4606-20; PMID:23143305; http://dx.doi.org/10.1172/JCI63287
89. Shim BS, Choi Y, Cheon IS, Song MK. Sublingual delivery of vaccines for the induction of mucosal immunity. Immune Netw 2013; 13:81-5; PMID:23885221; http://dx.doi.org/10.4110/in.2013.13.3.81
90. Pedersen G, Cox R. The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother 2012; 8:689-93; PMID:22495121; http://dx.doi.org/10.4161/hv.19568
91. Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis DJ. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One 2012; 7:e33736; PMID:22438987; http://dx.doi.org/10.1371/journal.pone.0033736
92. Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuère F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 2006; 176:2749-57; PMID:16493030; http://dx.doi.org/10.4049/jimmunol.176.5.2749
93. Klein K, Mann JF, Rogers P, Shattock RJ. Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines. Journal of controlled release: official journal of the Controlled Release Society 2014.
94. Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun 2008; 76:1940-51; PMID:18332214; http://dx.doi.org/10.1128/IAI.01484-07
95. Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirusassociated genital-tumor regression in mice. Mucosal Immunol 2013; 6:393-404; PMID:22968420; http://dx.doi.org/10.1038/mi.2012.83
96. Seavey MM, Mosmann TR. Estradiol-induced vaginal mucus inhibits antigen penetration and CD8(+) T cell priming in response to intravaginal immunization. Vaccine 2009; 27:2342-9; PMID:19428849; http://dx.doi.org/10.1016/j.vaccine.2009.02.025
97. Soler E, Parez N, Passet B, Dubuquoy C, Riffault S, Pillot M, Houdebine LM, Schwartz-Cornil I. Recombinant rotavirus inner core proteins produced in the milk of transgenic rabbits confer a high level of protection after intrarectal delivery. Vaccine 2007; 25:6373-80; PMID:17629366; http://dx.doi.org/10.1016/j.vaccine.2007.06.011
98. Alkadah A, Thiam F, Mounier M, Charpilienne A, Poncet D, Kohli E, Basset C. Different profile and distribution of antigen specific T cells induced by intranasal and intrarectal immunization with rotavirus 2/6-VLP with and without LT-R192G. Vaccine 2013; 31:1924-30; PMID:23453731; http://dx.doi.org/10.1016/j.vaccine.2013.02.019
99. Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, Richardson BA, Morton WR, Benveniste RE, Hu SL. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol 1999; 73:8201-15; PMID:10482571
100. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007; 178:7211-21; PMID:17513770; http://dx.doi.org/10.4049/jimmunol.178.11.7211
101. Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 2011; 29:1455-62; PMID:21185849; http://dx.doi.org/10.1016/j.vaccine.2010.12.031
102. Griffiths KL, Stylianou E, Poyntz HC, Betts GJ, Fletcher HA, McShane H. Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. PLoS One 2013; 8:e78312; PMID:24194918; http://dx.doi.org/10.1371/journal.pone.0078312
103. Rhee JH, Lee SE, Kim SY. Mucosal vaccine adjuvants update. Clinical and experimental vaccine research 2012; 1:50-63.
104. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896-903; PMID:14985487; http://dx.doi.org/10.1056/NEJMoa030595
105. da Hora VP, Conceic¸ão FR, Dellagostin OA, Doolan DL. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011; 29:1538-44; PMID:21163247; http://dx.doi.org/10.1016/j.vaccine.2010.11.091
106. Nawar HF, Arce S, Russell MW, Connell TD. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect Immun 2007; 75:621-33; PMID:17118982; http://dx.doi.org/10.1128/IAI.01009-06
107. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; http://dx.doi.org/10.4049/jimmunol.0901474
108. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, et al.; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7; PMID:19022320; http://dx.doi.org/10.1016/j.vaccine.2008.10.088
109. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 2011; 29:1421-30; PMID:21187177; http://dx.doi.org/10.1016/j.vaccine.2010.12.034
110. Fernandez S, Cisney ED, Ulrich RG. Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery. Clin Vaccine Immunol 2013; 20:1690-6; PMID:23986319; http://dx.doi.org/10.1128/CVI.00215-13
111. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 2012; 7:e41144; PMID:22829921; http://dx.doi.org/10.1371/journal.pone.0041144
112. Huang CF, Wu TC, Chu YH, Hwang KS, Wang CC, Peng HJ. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand J Immunol 2008; 68:502-10; PMID:18822109; http://dx.doi.org/10.1111/j.1365-3083.2008.02172.x
113. Pesce I, Monaci E, Muzzi A, Tritto E, Tavarini S, Nuti S, De Gregorio E, Wack A. Intranasal administration of CpG induces a rapid and transient cytokine response followed by dendritic and natural killer cell activation and recruitment in the mouse lung. J Innate Immun 2010; 2:144-59; PMID:20375632; http://dx.doi.org/10.1159/000254948
114. Jiang W, Sun R, Zhou R, Wei H, Tian Z. TLR-9 activation aggravates concanavalin A-induced hepatitis via promoting accumulation and activation of liver CD4+ NKT cells. J Immunol 2009; 182:3768-74; PMID:19265155; http://dx.doi.org/10.4049/jimmunol.0800973
115. McNally B, Willette M, Ye F, Partida-Sanchez S, Flaño E. Intranasal administration of dsRNA analog poly(I:C) induces interferon-α receptor-dependent accumulation of antigen experienced T cells in the airways. PLoS One 2012; 7:e51351; PMID:23236482; http://dx.doi.org/10.1371/journal.pone.0051351
116. Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010; 82:476-84; PMID:20087927; http://dx.doi.org/10.1002/jmv.21694
117. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011; 29:5731-9; PMID:21696869; http://dx.doi.org/10.1016/j.vaccine.2011.05.095
118. Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, et al. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012; 30:466-74; PMID:22051136; http://dx.doi.org/10.1016/j.vaccine.2011.10.058
119. Braga CJ, Rittner GM, Muñoz Henao JE, Teixeira AF, Massis LM, Sbrogio-Almeida ME, Taborda CP, Travassos LR, Ferreira LC. Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect Immun 2009; 77:1700-7; PMID:19204092; http://dx.doi.org/10.1128/IAI.01470-08
120. Braga CJ, Massis LM, Sbrogio-Almeida ME, Alencar BC, Bargieri DY, Boscardin SB, Rodrigues MM, Ferreira LC. CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 2010; 28:1373-82; PMID:19932669; http://dx.doi.org/10.1016/j.vaccine.2009.11.003
121. Hjelm BE, Kilbourne J, Herbst-Kralovetz MM. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum Vaccin Immunother 2013; 9:10; PMID:24280723
122. Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K. Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol 2013; 26:133-42; PMID:23509985; http://dx.doi.org/10.1089/vim.2012.0057
123. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007; 25:2085-94; PMID:17258843; http://dx.doi.org/10.1016/j.vaccine.2006.11.034
124. Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554; http://dx.doi.org/10.4049/jimmunol.179.5.3371
125. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-79; PMID:12874260; http://dx.doi.org/10.1084/jem.20030324
126. Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, Mori K, Taniguchi M, Hase K, Ohno H, Shimaoka T, et al. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 2008; 1:208-18; PMID:19079180; http://dx.doi.org/10.1038/mi.2008.2
127. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005; 175:3309-17; PMID:16116223; http://dx.doi.org/10.4049/jimmunol.175.5.3309
128. Youn HJ, Ko SY, Lee KA, Ko HJ, Lee YS, Fujihashi K, Boyaka PN, Kim SH, Horimoto T, Kweon MN, et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007; 25:5189-98; PMID:17548137; http://dx.doi.org/10.1016/j.vaccine.2007.04.081
129. Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 2011; 41:3312-22; PMID:21818755; http://dx.doi.org/10.1002/eji.201041359
130. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009; 100:1092-8; PMID:19302288; http://dx.doi.org/10.1111/j.1349-7006.2009.01135.x
131. Yoshino N, Endo M, Kanno H, Matsukawa N, Tsutsumi R, Takeshita R, Sato S. Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice. PLoS One 2013; 8:e61643; PMID:23593492; http://dx.doi.org/10.1371/journal.pone.0061643
132. Shin H, Iwasaki A. Generating protective immunity against genital herpes. Trends Immunol 2013; 34:487-94; PMID:24012144; http://dx.doi.org/10.1016/j.it.2013.08.001
133. Hammerschmidt SI, Friedrichsen M, Boelter J, Lyszkiewicz M, Kremmer E, Pabst O, Förster R. Retinoic acid induces homing of protective T and B cells to the gut after subcutaneous immunization in mice. J Clin Invest 2011; 121:3051-61; PMID:21737878; http://dx.doi.org/10.1172/JCI44262
134. Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, Choi YJ, Cho CS. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014; 35:2365-73; PMID:24342722; http://dx.doi.org/10.1016/j.biomaterials.2013.11.073
135. Yamamoto M, Pascual DW, Kiyono H. M cell-targeted mucosal vaccine strategies. Curr Top Microbiol Immunol 2012; 354:39-52; PMID:21688209; http://dx.doi.org/10.1007/82-2011-134
136. Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci U S A 2009; 106:4331-6; PMID:19246373; http://dx.doi.org/10.1073/pnas.0900029106
137. de Souza RD, Batista MT, Luiz WB, Cavalcante RC, Amorim JH, Bizerra RS, Martins EG, Ferreira LC. Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action. PLoS One 2014; 9:e87454; PMID:24475289; http://dx.doi.org/10.1371/journal.pone.0087454
138. Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165:3301-8; PMID:10975847; http://dx.doi.org/10.4049/jimmunol.165.6.3301
139. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36:1124-35; PMID:16568496; http://dx.doi.org/10.1002/eji.200535443
140. Smith DC, Lord JM, Roberts LM, Tartour E, Johannes L. 1st class ticket to class I: protein toxins as pathfinders for antigen presentation. Traffic 2002; 3:697-704; PMID:12230467; http://dx.doi.org/10.1034/j.1600-0854.2002.31001.x
141. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Science translational medicine 2013; 5:172ra20.
142. Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, Goldbaum FA, Zylberman V, Palermo MS. Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against Shiga toxins in mice. J Immunol 2013; 191:2403-11; PMID:23918978; http://dx.doi.org/10.4049/jimmunol.1300999
143. Gupta P, Singh MK, Singh Y, Gautam V, Kumar S, Kumar O, Dhaked RK. Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice. Vaccine 2011; 29:8094-100; PMID:21856355; http://dx.doi.org/10.1016/j.vaccine.2011.08.040
144. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; PMID:21908423; http://dx.doi.org/10.1182/blood-2011-01-329656
145. Johannes L, Tartour E. Correspondence to Creydt VP et al., Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells, Microbes Infect. 8(2) (2006) 410-419. Microbes and infection / Institut Pasteur 2006; 8:2331-2.
146. Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM. The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials 2008; 29:703-8; PMID:18006053; http://dx.doi.org/10.1016/j.biomaterials.2007.10.026
147. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21:341-6; PMID:12531630; http://dx.doi.org/10.1016/S0264-410X(02)00613-8
148. Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011; 23:414-20; PMID:21511452; http://dx.doi.org/10.1016/j.coi.2011.03.009
149. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24:254-62; PMID:16129526; http://dx.doi.org/10.1016/j.vaccine.2005.07.088
150. De Smet R, Allais L, Cuvelier C. Recent advances in oral vaccine development: Yeast-derived β-glucan particles. Hum Vaccin Immunother 2014; 10:10; PMID:24553259; http://dx.doi.org/10.4161/hv.28166
151. De Smet R, Demoor T, Verschuere S, Dullaers M, Ostroff GR, Leclercq G, Allais L, Pilette C, Dierendonck M, De Geest BG, et al. beta-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. Journal of controlled release: official journal of the Controlled Release Society 2013; 172:671-8.
152. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 2010; 28:6393-7; PMID:20493820; http://dx.doi.org/10.1016/j.vaccine.2010.05.019
153. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58; PMID:16491139; http://dx.doi.org/10.1038/nri1777
154. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009; 83:5726-34; PMID:19321609; http://dx.doi.org/10.1128/JVI.00207-09
155. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181:4955-64; PMID:18802099; http://dx.doi.org/10.4049/jimmunol.181.7.4955
156. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001; 166:3451-7; PMID:11207303; http://dx.doi.org/10.4049/jimmunol.166.5.3451
157. Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol 2008; 181:4188-98; PMID:18768876; http://dx.doi.org/10.4049/jimmunol.181.6.4188
158. Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 2012; 354:1-18; PMID:21053117; http://dx.doi.org/10.1007/82-2010-112
159. Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. The lancet. Respir Med 2013; 1:551-63
160. Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax(®). Oncoimmunology 2013; 2:e23687; PMID:23483762; http://dx.doi.org/10.4161/onci.23687
161. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, et al. Adjuvant MAGE-A3 immunotherapy in resected non-smallcell lung cancer: phase II randomized study results. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31:2396-403.
162. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2008; 3:735-44.
163. Li AV, Moon JJ, Abraham W, Suh H, Elkhader J, Seidman MA, Yen M, Im EJ, Foley MH, Barouch DH, et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Science translational medicine 2013; 5:204ra130.
164. Yu CI, Becker C, Wang Y, Marches F, Helft J, Leboeuf M, Anguiano E, Pourpe S, Goller K, Pascual V, et al. Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. Immunity 2013; 38:818-30; PMID:23562160; http://dx.doi.org/10.1016/j.immuni.2013.03.004
165. Wakabayashi A, Nakagawa Y, Shimizu M, Moriya K, Nishiyama Y, Takahashi H. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin. J Immunol 2008; 180:4000-10; PMID:18322209; http://dx.doi.org/10.4049/jimmunol.180.6.4000
166. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Suhartha N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, et al. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. J Immunol 2010; 185:2580-8; PMID:20644173; http://dx.doi.org/10.4049/jimmunol.0903231
167. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198:1023-34; PMID:14530375; http://dx.doi.org/10.1084/jem.20021348
168. Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, et al. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol 2008; 181:8112-9; PMID:19018004; http://dx.doi.org/10.4049/jimmunol.181.11.8112
169. Domingos-Pereira S, Derré L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, Nardelli-Haefliger D. Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. J Urol 2014; 191:814-22; PMID:23954582; http://dx.doi.org/10.1016/j.juro.2013.08.009
170. Decrausaz L, Domingos-Pereira S, Duc M, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. International journal of cancer Journal international du cancer 2011; 129:762-72.
171. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi.org/10.1056/NEJMoa0810097
172. Pages F. Tumor-associated immune parameters for personalized patient care. Science translational medicine 2013; 5:214fs42.
173. Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Molecular therapy: the journal of the American Society of Gene Therapy 2014; 22:18-27.
174. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
175. Petaja T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. International journal of cancer Journal international du cancer 2011; 129:2147-57.
176. Boelen A, Andeweg A, Kwakkel J, Lokhorst W, Bestebroer T, Dormans J, Kimman T. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 2000; 19:982-91; PMID:11115725; http://dx.doi.org/10.1016/S0264-410X(00)00213-9
177. Flipse J, Wilschut J, Smit JM. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 2013; 14:25-35; PMID:22998156
178. Ray SJ, Franki SN, Pierce RH, Dimitrova S, Koteliansky V, Sprague AG, Doherty PC, de Fougerolles AR, Topham DJ. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 2004; 20:167-79; PMID:14975239; http://dx.doi.org/10.1016/S1074-7613(04)00021-4
179. Tang VA, Rosenthal KL. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J Reprod Immunol 2010; 87:39-44; PMID:20688399; http://dx.doi.org/10.1016/j.jri.2010.06.155
180. Kelly KA, Chan AM, Butch A, Darville T. Two different homing pathways involving integrin β7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following Chlamydia muridarum infection. Am J Reprod Immunol 2009; 61:438-45; PMID:19392981; http://dx.doi.org/10.1111/j.1600-0897.2009.00704.x